Eli Lilly, an American pharmaceutical company, plans to disclose the results of a Phase 3 clinical trial for its obesity medication, Zepbound, which is also being developed as an oral drug ...

Eli Lilly has agreed ... treatment program. The new company will be owned by Scorpion's current shareholders, while Lilly will hold a minority stake. A timeline for the transaction wasn't disclosed.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Toward the mid of January, Cramer discussed Eli Lilly’s (NYSE:LLY) stock drop, noting that the company had projected $58 to $61 billion in revenue for the coming year, driven by its GLP-1 drugs ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer's radar. Jim Cramer, host of Mad Money, shared his thoughts on ...